Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.080
-0.030 (-2.70%)
Jun 5, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 25 employees as of December 31, 2025. The number of employees decreased by 12 or -32.43% compared to the previous year.
Employees
25
Change
-12
Growth
-32.43%
Revenue / Employee
$3,600
Profits / Employee
-$938,840
Market Cap
33.67M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 25 | -12 | -32.43% |
| Sep 30, 2025 | 25 | -12 | -32.43% |
| Jun 30, 2025 | 27 | -10 | -27.03% |
| Mar 31, 2025 | 31 | -18 | -36.73% |
| Dec 31, 2024 | 37 | -12 | -24.49% |
| Sep 30, 2024 | 37 | -12 | -24.49% |
| Dec 31, 2023 | 49 | 0 | - |
| Dec 31, 2022 | 49 | 17 | 53.13% |
| Dec 31, 2021 | 32 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| Senti Biosciences Holdings | 39 |
| Boundless Bio | 28 |
| Daré Bioscience | 24 |
| INmune Bio | 21 |
| Lisata Therapeutics | 21 |
| ABVC BioPharma | 19 |
ATNM News
- 1 day ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 2 days ago - Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026 - TheFly
- 2 days ago - Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PRNewsWire
- 2 days ago - Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - PRNewsWire
- 4 days ago - Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer - TheFly
- 4 days ago - Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development - PRNewsWire
- 4 days ago - Actinium Pharmaceuticals presents new radiochemistry data at SNMMI - TheFly
- 4 days ago - Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates - PRNewsWire